Jade Biosciences Reports Q3 2025 Financial Results
Jade Biosciences reported a Q3 2025 net loss of $25.2 million due to increased R&D and G&A expenses. The company completed a merger and reverse stock split, presented promising preclinical data, and initiated a Phase 1 study. They raised $135 million to extend their cash runway into 2028. Analysts rate JBIO stock as a Buy with a $28 target, but Spark's AI Analyst views it as Underperform due to financial challenges. Jade Biosciences focuses on therapies for autoimmune diseases.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jade Biosciences ( (JBIO) ) just unveiled an announcement.
On April 28, 2025, Jade Biosciences, formerly Aerovate Therapeutics, completed a business merger, resulting in a name change and a reverse stock split. The company presented promising preclinical data for JADE101 and initiated a Phase 1 study, with interim results expected in 2026. They also introduced JADE201, targeting autoimmune diseases, and completed a $135 million private placement to extend their cash runway into 2028. The third quarter of 2025 saw increased R&D and G&A expenses, leading to a net loss of $25.2 million.
The most recent analyst rating on (JBIO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.
Spark’s Take on JBIO Stock
According to Spark, TipRanks’ AI Analyst, JBIO is a Underperform.
Aerovate Therapeutics’ stock score reflects substantial financial challenges, including zero revenue and growing losses, which heavily weigh on the overall score. While there is positive momentum in technical analysis and significant corporate events such as the merger with Jade Biosciences, the negative valuation and financial instability are major concerns. The stock remains highly speculative with risks due to its financial performance.
To see Spark’s full report on JBIO stock, click here.
More about Jade Biosciences
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL.
Average Trading Volume: 140,302
Technical Sentiment Signal: Hold
Current Market Cap: $326.3M
